Check out some of the companies making the biggest moves at midday: Hims & Hers Health — The telemedicine company’s stock rose 3%. Bank of America raised its stock from underperform to neutral after Novo Nordisk dropped its patent infringement lawsuit against Hims, and the companies agreed to allow Hims to sell Novo’s Ozempic and Wigovy drugs on its platform. Analyst Allen Lutz said in a note Tuesday that Novo’s move to drop the lawsuit is “clearly positive in our view as it removes litigation and its associated credit risk, which is the primary driver of the new multiple increase in our model.” BioNTech — The German biotech company’s U.S.-traded shares soared more than 20%. BioNTech announced that its co-founders, Drs. Ugur Şahin and Ozlem Tureci, were leaving to form and lead an independent company. Separately, BioNTech reported a fourth-quarter net loss of 305 million euros ($355.75 million). SolarEdge Technologies — Solar stocks rose nearly 10% after Bank of America upgraded the stock to neutral from underperform. The Wall Street firm said SolarEdge’s margin trajectory, earnings pace and liquidity are all sufficiently stable to significantly reduce downside risks. West Pharmaceutical Services — The drug company fell 6% after CEO and Chairman Eric Green announced he would step down in the second half of 2026. United Natural Foods — Shares fell nearly 3%. The grocery distributor reported second-quarter sales of $7.95 billion, short of the $8.11 billion expected by analysts surveyed by FactSet. United Natural also lowered its full-year revenue forecast, now expecting a range of $31 billion to $31.4 billion, compared to its previous forecast of $31.6 billion to $32 billion. Kohl’s — Shares rose 1% after Kohl’s reiterated that it is working on a turnaround plan. Kohl’s shares fell after disappointing fourth-quarter sales of $4.97 billion, below the LSEG consensus of $5.03 billion, but fourth-quarter adjusted earnings of $1.07 per share beat expectations of 85 cents per share. Casey’s General Stores — The convenience store chain rose nearly 2%. Third-quarter earnings were $3.49 per share, beating the FactSet consensus estimate of $3 per share. Revenue was lower than analysts expected, coming in at $3.92 billion, compared to the consensus estimate of $4.04 billion. UWM Holdings – Mortgage loan originator rose nearly 7%. UWM raised its first-quarter revenue guidance to $800 million to $900 million, up from its previous estimate of $650 million to $850 million. The new forecast beat the FactSet consensus estimate of $641.3 million. Rivian Automotive — Shares of this electric vehicle maker rose about 6% after an upgrade by TD Cowen. The bank changed its rating on Rivian from hold to buy on the belief that demand for electric vehicles will revive at Vertex Pharmaceuticals ahead of the launch of the company’s new R2 SUV (cheaper and smaller than the R1S model). Shares of Vertex Pharmaceuticals rose 8% after the biotech company announced that a drug met its goals in late-stage trials for IgA nephropathy, a chronic disease that can lead to kidney failure. — CNBC’s Darla Mercado, Sarah Ming, Davis Giangiulio, Michelle Fox, Yun Li and Pia Xin contributed to the report Markets change and headlines fade, but the core principles of building long-term wealth remain the same. Join us for the third annual CNBC Pro LIVE. Investors from all backgrounds, from financial professionals to everyday individuals, come together to cut through the noise and gain actionable strategies for smarter, more disciplined investing. No matter where you start, you’ll leave with clearer thinking and a stronger strategy. Enter your email address here to get your discount code.
